Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies

被引：0
|
作者：
T. Sakakida
T. Ishikawa
Y. Chihara
S. Harita
J. Uchino
Y. Tabuchi
S. Komori
J. Asai
T. Narukawa
A. Arai
H. Tsunezuka
T. Kosuga
H. Konishi
M. Moriguchi
H. Yasuda
F. Hongo
M. Inoue
S. Hirano
O. Ukimura
Y. Itoh
T. Taguchi
K. Takayama
机构：
[1] Kyoto Prefectural University of Medicine,Department of Gastroenterology and Hepatology, Graduate School of Medical Science
[2] Kyoto Prefectural University of Medicine,Outpatient Oncology Unit, University Hospital
[3] Kyoto Prefectural University of Medicine,Department of Pulmonary Medicine, Graduate School of Medical Science
[4] Kyoto Prefectural University of Medicine,Department of Dermatology, Graduate School of Medical Science
[5] Kyoto Prefectural University of Medicine,Department of Urology, Graduate School of Medical Science
[6] Kyoto Prefectural University of Medicine,Department of Otolaryngology
[7] Kyoto Prefectural University of Medicine,Head and Neck Surgery, Graduate School of Medical Science
[8] Kyoto Prefectural University of Medicine,Division of Thoracic Surgery, Department of Surgery, Graduate School of Medical Science
[9] Kyoto Prefectural University of Medicine,Division of Digestive Surgery, Department of Surgery, Graduate School of Medical Science
[10] Kyoto Prefectural University of Medicine,Division of Endocrine and Breast Surgery, Department of Surgery, Graduate School of Medical Science
来源：
Clinical and Translational Oncology | 2020年 / 22卷
关键词：
Immune-related adverse events; Programmed cell death 1 blockade; Immune checkpoint inhibitors; Antinuclear antibodies; Autoimmune diseases;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：919 / 927
页数：8
相关论文
共 50 条
  • [31] Peripheral CD8+CD28+T lymphocytes predict the efficacy and safety of PD-1/PD-L1 inhibitors in cancer patients
    Geng, Ruixuan
    Tang, Hui
    You, Tingting
    Xu, Xiuxiu
    Li, Sijian
    Li, Zepeng
    Liu, Yuan
    Qiu, Wei
    Zhou, Na
    Li, Ningning
    Ge, Yuping
    Guo, Fuping
    Sun, Yuhong
    Wang, Yingyi
    Li, Taisheng
    Bai, Chunmei
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [32] Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade
    Eltahir, Mohamed
    Isaksson, Johan
    Mattsson, Johanna Sofia Margareta
    Karre, Klas
    Botling, Johan
    Lord, Martin
    Mangsbo, Sara M.
    Micke, Patrick
    CANCERS, 2021, 13 (13)
  • [33] From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway
    Zhan, Mei-Miao
    Hu, Xue-Qin
    Liu, Xiu-Xiu
    Ruan, Ban-Feng
    Xu, Jun
    Liao, Chenzhong
    DRUG DISCOVERY TODAY, 2016, 21 (06) : 1027 - 1036
  • [34] Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
    Brancatella, Alessandro
    Lupi, Isabella
    Montanelli, Lucia
    Ricci, Debora
    Viola, Nicola
    Sgro, Daniele
    Antonangeli, Lucia
    Sardella, Chiara
    Brogioni, Sandra
    Piaggi, Paolo
    Molinaro, Eleonora
    Bianchi, Francesca
    Aragona, Michele
    Antonuzzo, Andrea
    Sbrana, Andrea
    Lucchesi, Maurizio
    Chella, Antonio
    Falcone, Alfredo
    del Prato, Stefano
    Elisei, Rossella
    Marcocci, Claudio
    Caturegli, Patrizio
    Santini, Ferruccio
    Latrofa, Francesco
    JOURNAL OF THE ENDOCRINE SOCIETY, 2021, 5 (09)
  • [35] Comparative Safety of PD-1/PD-L1 Inhibitors for Cancer Patients: Systematic Review and Network Meta-Analysis
    Huang, Ya-Fang
    Xie, Wen-Jie
    Fan, Hai-Yu
    Du, Juan
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [36] Meta-Analysis of Efficacy From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
    Xu, Li
    Yan, Xin
    Ding, Weiyue
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [37] PD-1 and PD-L1 inhibitors in oesophago-gastric cancers
    Telli, Tugba Akin
    Bregni, Giacomo
    Camera, Silvia
    Deleporte, Amelie
    Hendlisz, Main
    Sclafani, Francesco
    CANCER LETTERS, 2020, 469 : 142 - 150
  • [38] PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
    Munari, Enrico
    Mariotti, Francesca R.
    Quatrini, Linda
    Bertoglio, Pietro
    Tumino, Nicola
    Vacca, Paola
    Eccher, Albino
    Ciompi, Francesco
    Brunelli, Matteo
    Martignoni, Guido
    Bogina, Giuseppe
    Moretta, Lorenzo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (10)
  • [39] Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
    Anand, Kartik
    Sahu, Geetanjali
    Burns, Ethan
    Ensor, Allyne
    Ensor, Joe
    Pingali, Sai Ravi
    Subbiah, Vivek
    Iyer, Swaminathan P.
    ESMO OPEN, 2020, 5 (04)
  • [40] Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
    Cheng, Chao
    Zhuge, Lingdun
    Xiao, Xin
    Luan, Siyuan
    Yuan, Yong
    FRONTIERS IN ONCOLOGY, 2022, 12
12345